HORMONE-RECEPTOR-POSITIVE BREAST CANCER
Clinical trials for HORMONE-RECEPTOR-POSITIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HORMONE-RECEPTOR-POSITIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for HORMONE-RECEPTOR-POSITIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Landmark trial may spare thousands of women from chemo
Disease control OngoingThis large phase 3 trial studied over 10,000 women with early-stage, hormone-receptor-positive breast cancer that hasn't spread to lymph nodes. It used the Oncotype DX test to assign women to hormone therapy alone or hormone therapy plus chemotherapy based on their recurrence sco…
Matched conditions: HORMONE-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 02, 2026 01:00 UTC
-
Immune booster before chemo shows promise for tough breast cancer
Disease control OngoingThis study tests whether giving two immunotherapy drugs (decitabine and pembrolizumab) before standard chemotherapy can help the immune system attack HER2-negative breast cancer more effectively. About 46 adults with locally advanced disease will receive a short course of these d…
Matched conditions: HORMONE-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Virginia Commonwealth University • Aim: Disease control
Last updated Jul 02, 2026 01:00 UTC
-
New cancer drug candidate BG-68501 enters first human trials
Disease control OngoingThis early-phase study tests a new drug called BG-68501 in people with advanced solid tumors that have not responded to standard treatments. The drug targets a protein (CDK2) that helps cancer cells grow. The trial will check safety, find the right dose, and see if the drug shrin…
Matched conditions: HORMONE-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE1 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Vitamin d and exercise may fight bone loss in breast cancer survivors
Disease control OngoingThis study looks at whether high-dose vitamin D and a home exercise program (walking and strength training) can help prevent bone loss in women being treated for breast cancer. About 191 postmenopausal women with early-stage breast cancer will take either vitamin D or a placebo, …
Matched conditions: HORMONE-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: University of Rochester • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New combo shot aims to stop early breast cancer from returning
Disease control OngoingThis Phase 2 trial is testing whether a combination of two targeted drugs (trastuzumab and pertuzumab) given as a single shot under the skin, along with standard hormone therapy, can prevent cancer from returning after surgery in people with early-stage, hormone receptor-positive…
Matched conditions: HORMONE-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Promising drug combo aims to shrink breast tumors before surgery
Disease control OngoingThis study tests whether adding the targeted drug pyrotinib to standard chemotherapy can better shrink tumors before surgery in people with a common type of early breast cancer (HR-positive, HER2-low). About 160 adults with high-risk, early-stage breast cancer will be randomly as…
Matched conditions: HORMONE-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE3 • Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New drug combo shows promise for Hard-to-Treat breast cancer
Disease control OngoingThis study tests whether adding the drug pyrotinib to standard chemotherapy before surgery can improve outcomes for women with stage II to III hormone receptor-positive, HER2-negative breast cancer that also has high levels of the HER4 protein. About 140 participants will receive…
Matched conditions: HORMONE-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New drug shows promise for Hard-to-Treat cancers
Disease control OngoingThis study tests a new drug, DS-1062a, in people with advanced solid tumors like lung and breast cancer that haven't responded to other treatments. It's the first time this drug is being used in humans, so the main goals are to check safety, find the right dose, and see if it hel…
Matched conditions: HORMONE-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE1 • Sponsor: Daiichi Sankyo Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New drug combo shows promise in shrinking breast tumors before surgery
Disease control OngoingThis study tests a combination of two drugs, lenvatinib and letrozole, given before surgery to postmenopausal women with a common type of breast cancer (hormone receptor positive). The goal is to see if the drugs can shrink the tumor enough to improve surgical outcomes. About 40 …
Matched conditions: HORMONE-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: National University Hospital, Singapore • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Immunotherapy drug cemiplimab takes on aggressive breast cancer in new trial
Disease control OngoingThis phase 2 trial is testing whether adding the immunotherapy drug cemiplimab (Libtayo) to standard chemotherapy can eliminate more cancer before surgery in people with high-risk or locally advanced breast cancer. The study enrolls 36 participants with either hormone receptor-po…
Matched conditions: HORMONE-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Jun 26, 2026 13:59 UTC
-
New hope for breast cancer patients: drug may tame hot flashes without hormones
Symptom relief OngoingThis study tests fezolinetant, a non-hormonal drug, for treating hot flashes in women with hormone-positive breast cancer who are on hormone therapy. About 984 women will take either fezolinetant or a placebo daily for a year. The goal is to see if fezolinetant reduces the number…
Matched conditions: HORMONE-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE3 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 14:03 UTC
-
New hope for breast cancer patients: drug may tame Treatment-Linked hot flashes
Symptom relief OngoingThis study tests a drug called elinzanetant to see if it can reduce hot flashes in women with hormone-receptor positive breast cancer who are on hormone-blocking therapy. About 474 women will take either the drug or a placebo for 12 weeks, then all will receive the drug for up to…
Matched conditions: HORMONE-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE3 • Sponsor: Bayer • Aim: Symptom relief
Last updated Jun 27, 2026 14:01 UTC
-
Could taking pills every other day help breast cancer patients stick with treatment?
Symptom relief OngoingThis study looks at whether starting hormone therapy every other day for one month, then switching to daily, helps women with early breast cancer take their medication as prescribed. About 240 participants will be randomly assigned to either the standard daily dose or the gradual…
Matched conditions: HORMONE-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE4 • Sponsor: Ottawa Hospital Research Institute • Aim: Symptom relief
Last updated Jun 27, 2026 12:03 UTC